Altimmune, Inc. (ALT): Results of Operations and Financial Condition
Altimmune, Inc. (ALT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Altimmune Announces Second Quarter 2026 Financial Results and Business Update Initiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2 trial in AUD Completed patient enrollment in RESTORE Phase 2 trial in ALD $519 million
How this was made
The 30-second read
Why it matters
The 8-K combines (1) Phase 3 start for MASH, (2) positive Phase 2 AUD topline with registrationally recognized endpoints, and (3) ALD Phase 2 enrollment completion plus protocol amendment and a revised hierarchical endpoint assessment plan.
Market read
Investors get fresh, time-sensitive trial and regulatory-path updates plus updated cash position, which can drive probability re-rating and near-term trading in ALT.
What to watch
R&D and G&A expense increases and the longer-dated ALD topline (2H 2027) could temper enthusiasm, and AUD path depends on the planned End-of-Phase 2 meeting outcomes.
Altimmune Announces Second Quarter 2026 Financial Results and Business Update
The company advanced all three pemvidutide programs, initiating PERFORMA Phase 3 in MASH, reporting positive RECLAIM Phase 2 topline data in AUD, and completing RESTORE Phase 2 enrollment in ALD, while reporting $519 million in cash, cash equivalents and investments.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and development expensesGAAP | $18.7 million | – | – |
| Direct costs related to pemvidutide development activitiesGAAP | $11.6 million | – | – |
| General and administrative expensesGAAP | $7.6 million | – | – |
| Interest incomeGAAP | $4.5 million | – | – |
| Net lossGAAP | $22.8 million | – | – |
| Net loss per shareGAAP | $0.12 net loss per share | – | – |
| Cash, cash equivalents and investmentsother | $519 million | – | – |
| Cash and cash equivalentsother | $ 63,008 | – | – |
| Short-term investmentsother | 263,273 | – | – |
| Long-term investmentsother | 192,247 | – | – |
| Term loan, noncurrentother | 34,742 | – | – |
2029 and second half of 2027 outlook
- Note52-week data readout anticipated in 2029 for the global PERFORMA Phase 3 MASH trial
- NoteThe Company expects to report RESTORE Phase 2 trial topline data in the second half of 2027
What drove it
- R&D expense increased primarily due to the ongoing ALD trial and startup costs for the PERFORMA Phase 3 trial in MASH.
- The increase in R&D expense was partially offset by lower expenses following completion of the IMPACT Phase 2b trial in MASH, which was ongoing in 2025.
- G&A expense increased primarily due to higher professional services and compensation expenses.
- Pemvidutide received Breakthrough Therapy Designation from the FDA for MASH based on 24-week data from the IMPACT Phase 2b trial.
- RECLAIM Phase 2 achieved a statistically significant and clinically meaningful reduction in heavy drinking days, its primary endpoint.
- RECLAIM also met secondary endpoints including a 2-level reduction in WHO-risk drinking levels and zero heavy drinking days.
- The FDA granted Fast Track designation to pemvidutide for AUD.
Concerns
- Net loss was $22.8 million for the three months ended June 30, 2026, compared to $22.1 million in the same period in 2025.
- R&D expense was $18.7 million for the three months ended June 30, 2026, compared to $17.2 million in the same period in 2025, as the company began PERFORMA Phase 3 startup activities.
- G&A expense was $7.6 million for the three months ended June 30, 2026, compared to $5.7 million in the same period in 2025.
- PERFORMA 52-week data are anticipated in 2029.
- RESTORE topline data are expected in the second half of 2027.
What to watch
- Initiation and execution of the global PERFORMA Phase 3 MASH trial, with 52-week data readout anticipated in 2029.
- The Company's planned End-of-Phase 2 meeting request with the FDA and engagement with European regulatory agencies regarding a path forward in AUD.
- RESTORE Phase 2 topline data expected in the second half of 2027.
- RESTORE's amended protocol, under which the primary endpoint of change from baseline in Liver Stiffness Measurement will be assessed hierarchically at Week 48 and then at Week 24.
- The planned relocation of the corporate headquarters to Morristown, New Jersey later in 2026.
Balance sheet and cash flow
- Cash, cash equivalents and investments totaled $519 million as of June 30, 2026.
- Cash and cash equivalents were $ 63,008 as of June 30, 2026, compared to $ 43,760 as of December 31, 2025. Amounts are in thousands.
- Total cash, cash equivalents and restricted cash were 63,050 as of June 30, 2026, compared to 43,802 as of December 31, 2025. Amounts are in thousands.
- Short-term investments were 263,273 as of June 30, 2026, compared to 229,696 as of December 31, 2025. Amounts are in thousands.
- Long-term investments were 192,247 as of June 30, 2026, compared to — as of December 31, 2025. Amounts are in thousands.
- Total assets were $ 527,212 as of June 30, 2026, compared to $ 279,929 as of December 31, 2025. Amounts are in thousands.
- Term loan, noncurrent was 34,742 as of June 30, 2026, compared to 34,287 as of December 31, 2025. Amounts are in thousands.
- Total liabilities were 53,004 as of June 30, 2026, compared to 55,037 as of December 31, 2025. Amounts are in thousands.
- In April 2026, the Company completed an oversubscribed public offering of common stock, pre-funded warrants, and stock warrants, resulting in gross proceeds of $225.0 million.
Analysis
Altimmune's quarter was defined by clinical execution rather than reported commercial financial metrics. The company initiated the global PERFORMA Phase 3 trial in MASH, announced positive topline RECLAIM Phase 2 results in AUD, and completed enrollment in RESTORE Phase 2 in ALD. RECLAIM met its primary endpoint of reducing heavy drinking days and met secondary endpoints of a 2-level reduction in WHO-risk drinking levels and zero heavy drinking days.
R&D expense was $18.7 million, compared with $17.2 million in the same period in 2025. The company attributed the increase to the ongoing ALD trial and PERFORMA Phase 3 startup costs, partly offset by reduced spending after the IMPACT Phase 2b MASH trial was completed. G&A expense was $7.6 million, compared with $5.7 million in the same period in 2025, driven by professional services and compensation expenses. Net loss was $22.8 million, or $0.12 net loss per share, compared with $22.1 million, or $0.27 net loss per share, in the same period in 2025.
Liquidity was materially strengthened by the April 2026 public offering, which generated gross proceeds of $225.0 million. The company reported $519 million in cash, cash equivalents and investments as of June 30, 2026. Its balance sheet also listed 34,742 of noncurrent term loan as of June 30, 2026, with balance-sheet amounts presented in thousands.
The development timeline places the most material disclosed near-term clinical catalyst in the second half of 2027, when the company expects RESTORE topline data. RESTORE's amended protocol shifts the primary endpoint assessment to a hierarchical evaluation at Week 48 and then Week 24, while retaining secondary endpoints on ELF score, alcohol consumption and body weight. PERFORMA is a longer-duration program, with 52-week data readout anticipated in 2029.
Management's strategic focus is expanding pemvidutide across MASH, AUD and ALD. Regulatory designations include Breakthrough Therapy Designation for MASH and Fast Track designation for AUD. The next operational items are regulatory discussions for AUD, execution of PERFORMA, and delivery of RESTORE data; the filing provided no revenue, margin, operating-income, cash-flow or financial-expense guidance figures.
Management, verbatim
We have achieved several important milestones as we continue to successfully execute our strategy, including the initiation of the PERFORMA Phase 3 MASH trial and positive topline data from the RECLAIM Phase 2 AUD trial.
Jerry Durso, Chief Executive Officer and Chairman of the Board of Altimmune
The team remains focused on advancing our differentiated pemvidutide franchise in both MASH and AUD, each an area of unmet need with substantial future sales potential.
Jerry Durso, Chief Executive Officer and Chairman of the Board of Altimmune
Not in the filing
stated, not guessed- Total revenue and prior-year revenue were not reported.
- Segment revenue, segment comparisons and segment drivers were not reported.
- Gross profit, gross margin and operating income were not reported.
- Non-GAAP financial metrics were not reported.
- Prior-quarter comparisons for R&D expense, G&A expense, interest income, net loss and net loss per share were not reported.
- Percentage year-over-year and quarter-over-quarter changes for reported financial metrics were not reported.
- Operating cash flow and free cash flow were not reported.
- Share repurchases, dividends and other capital-return amounts were not reported.
- Formal revenue, gross-margin, operating-expense and tax-rate guidance were not reported.
- A prior quarterly outlook was not provided.
- Full stockholders' equity information was not included in the supplied filing text.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Altimmune is a late clinical-stage biopharma developing pemvidutide for MASH, AUD, and ALD, with FDA designations already in place.
Ticker impact
Altimmune disclosed PERFORMA Phase 3 initiation for MASH, positive RECLAIM Phase 2 AUD topline, and RESTORE Phase 2 ALD enrollment completion.
Likely positive bias for ALT as investors price higher odds of registrational progress, with volatility around FDA interactions and future topline timing.
The filing is a primary disclosure (8-K) with multiple trial milestones and explicit FDA designations (Breakthrough, Fast Track) and a stated ALD topline expectation in 2H 2027.
Market effects
Adds incremental sentiment to late-stage liver-disease and addiction biopharma, but impact is company-specific rather than sector-wide.
Limited regional spillover; primarily affects US small/mid-cap biotech sentiment.
Modest, as the trials are global but the disclosure is US regulatory and investor-focused.
Counterpoint
Despite multiple milestones, there is no new Phase 3 efficacy data yet, so the market may fade the news until 2029 readout or clearer FDA guidance.
Key entities
- issuerAltimmune, Inc.
Nasdaq-listed developer of pemvidutide; reported Q2 2026 financials and multiple clinical trial milestones in an 8-K.
- drug_candidatePemvidutide
Investigational dual glucagon/GLP-1 receptor agonist being studied in MASH, AUD, and ALD.
- regulatorFDA
Granted Breakthrough Therapy Designation for MASH and Fast Track designation for AUD, shaping regulatory expectations.
